AKT1 and major depressive disorder: Extensive research indicates that medications can modulate neuronal or synaptic function (Yan et al., 2022) via the PI3K/Akt signaling pathway, thereby influencing the nervous system and potentially treating neurological disorders like depression and Alzheimer’s disease (Yang et al., 2020; Li et al., 2021).